Do We Actually Need Aging Clocks?

Few ideas in longevity science have spread faster than the promise of the aging clock. The sales pitch is simple enough to fit on a landing page: run a blood test, saliva sample, scan, wearable feed, or other biological readout through an algorithm, and out comes your “biological age” — a cleaner, more revealing number than the one on your passport. In the best version of that story, aging clocks help researchers test interventions faster, help clinicians identify risk earlier, and help people understand whether they are aging well or badly. In the worst version, they collapse a complicated biology into a seductive number that looks more precise than it really is. The serious question is no longer whether aging clocks are interesting. It is whether we actually need them.

There are good reasons the field keeps returning to the idea. Human aging is slow, heterogeneous, and expensive to study directly. Lifespan is impractical as a trial endpoint for most interventions, and healthspan is real but hard to compress into a single fast measure. That is why the aging-biomarker field has become so important. A 2023 Cell framework described biomarkers of aging as “critically important tools” for identifying and evaluating longevity interventions over realistic timeframes, while also stressing that the field still lacks shared standards and consensus for validation.

So the answer to the headline question is not a clean yes or no. We probably do need aging clocks — but not in the way many people currently talk about them. What the field needs most is not one universal “true age” machine. It needs validated, context-specific measures that are useful for particular jobs: enriching clinical trials, monitoring response, stratifying risk, and connecting molecular changes to clinically meaningful outcomes. The real argument, then, is less about whether clocks should exist than about what kind of clocks are worth building and what evidence they should have to earn their place.

Why aging clocks became so attractive

The attraction is obvious. In the 2026 npj Aging perspective bluntly titled “Do we actually need aging clocks?”, the authors note that biological age is pursued for three main reasons: as a potential surrogate endpoint in geroprotector trials, as a way to understand underlying aging processes, and as a way to represent overall health status in a single compact measure. That is powerful in principle. If a biomarker could tell researchers in months what lifespan studies take years or decades to show, it would change the economics of longevity science.

That hope also explains why clocks have proliferated so quickly. The same paper notes that models have now been trained on DNA methylation, plasma proteins, urine metabolites, clinical blood tests, facial images, X-rays, and many other inputs. More recently, clocks have expanded into wearable streams and organ-specific models. The field is no longer asking only whether a methylation clock can estimate age. It is asking which biological layer — epigenetic, proteomic, physiological, behavioral, or multimodal — is most useful for a given task.

That expansion matters because aging itself is not one thing. The 2023 biomarker framework emphasizes that different biomarkers may capture different aspects of aging, and that it may be unrealistic to expect a single biomarker to capture all aspects of biological aging and satisfy every criterion of feasibility, relevance, predictive power, and responsiveness to interventions. In other words, the field’s own consensus view is already pushing away from the fantasy of one master clock.

The strongest critique: maybe we need better prediction, not more clocks

The most serious challenge to the aging-clock boom is not that biological aging is fake. It is that biological age may be too abstract a target when what clinicians and trialists really need is direct prediction of meaningful outcomes. The 2026 npj Aging critique makes this point explicitly. By comparing clocks with expert risk scores, direct outcome predictors, and emerging large health models, the authors argue that researchers should have to justify why a clock adds value over established alternatives. They also note that direct outcome prediction — predicting measurable health outcomes like disease onset, functional decline, or mortality directly from features — may sometimes be more useful than predicting an intermediate quantity called biological age.

This is not a trivial objection. If a model can predict heart failure, disability, dementia risk, or mortality better than a biological-age summary number can, then the summary number may be more elegant than necessary. A neat clock can compress information for non-specialists, but that does not automatically make it the best scientific or clinical tool. The same npj Aging paper argues that one should ask whether striving for a better biological-age estimate, rather than improving direct health-outcome prediction, is truly worthwhile.

That critique lands hardest on clocks sold as universal truth machines. A clock that says you are “57 biologically” may be psychologically compelling, but if it cannot clearly outperform existing risk models or help guide an actual decision, it risks becoming more narrative device than medical instrument. That is one reason the field’s most careful voices increasingly focus on context of use rather than abstract superiority.

The validation problem is even bigger than the hype problem

Even if one accepts the basic logic of aging clocks, the next problem is validation. A 2024 review on biomarker validation notes that no consensus yet exists on how biomarkers of aging should be validated before clinical translation, and that there are still no recommended regulatory guidelines standardizing their development, measurement, or validation in the way disease biomarkers are often handled. The authors stress that clinical utility remains to be proven prospectively: aging biomarkers will need to show that they improve how patients feel, function, and survive, not merely that they correlate with other things in retrospective datasets.

This is where many public discussions run ahead of the evidence. Observational association is not the same thing as intervention sensitivity, and cross-sectional performance is not the same thing as longitudinal usefulness. The validation review explicitly notes that cross-sectional studies cannot establish within-individual sensitivity to change — a key requirement if clocks are going to be used in clinical trials. That matters because a clock that predicts age or mortality in a cohort is not automatically a good readout of whether a drug, diet, or exercise program truly changed the biology of aging in one person.

The 2026 npj Aging paper adds another, often neglected problem: uncertainty. It points out that most published aging clocks provide point estimates without confidence intervals and that metrics like mean absolute error cannot substitute for true uncertainty estimates, especially when a model is applied outside the data distribution it was trained on. The authors specifically warn that applying clocks outside their domain — for example across tissues, countries, ethnicities, assays, or experimental contexts unlike the training data — introduces epistemic uncertainty that is rarely quantified.

That is not a side note. It cuts to the heart of a lot of rejuvenation and consumer testing rhetoric. If a clock has not been shown to work robustly in the exact setting where it is being used, the number it returns may be less a measurement than a projection.

Yet clocks are getting better — and more specific

The critique, however, should not be mistaken for defeat. The field is improving, and some of the newer work shows why clocks remain compelling. A 2025 review in Biogerontology distinguishes first-generation epigenetic clocks, which were trained mainly to predict chronological age, from next-generation clocks, which are trained to associate with health, lifestyle, and age-related outcomes. The review concludes that next-generation models tend to associate with more health and disease signals, are often more predictive of age-related outcomes, and appear more responsive to interventions. It suggests they should generally be prioritized for health-oriented and interventional studies. That is not the last word, but it is an important shift.

More importantly, the field is moving away from generic whole-body clocks toward more interpretable and more clinically anchored versions. In 2025, researchers reported a blood-based intrinsic capacity methylation clock trained on cognition, locomotion, psychological well-being, sensory abilities, and vitality. In the Framingham Heart Study, the authors said this IC clock outperformed first- and second-generation epigenetic clocks in predicting all-cause mortality and was strongly associated with immune, inflammatory, functional, and lifestyle measures. That is notable because it ties the clock to function rather than to age prediction alone.

The same year brought organ-specific proteomic clocks that predicted disease onset, progression, and mortality beyond clinical and genetic risk factors, with brain aging most strongly linked to mortality. Those models matter not because they prove the field has solved biological age, but because they are more biologically interpretable than a single monolithic clock. Instead of pretending aging is one scalar variable, they suggest that different organs may age at different rates, with different implications.

Other recent work has widened the input side even further. A 2025 Nature Communications study described a wearable-based clock, PpgAge, derived from photoplethysmography data, which associated with disease and behavior and showed sensitivity to physiological changes over time; in that study, elevated PpgAge gap predicted incident heart disease events while also tracking behaviors such as smoking, exercise, and sleep. Another 2025 Nature Communications paper introduced the Health Octo Tool, a multidimensional system using disease states, walking speed, disability, and other metrics, which the authors said outperformed frailty index approaches for several outcomes and captured heterogeneity in aging across organ systems.

Taken together, these studies suggest that the future of clocks may be less about one number that rules them all and more about a family of biologically and clinically grounded estimators.

So what do we actually need?

The most sensible answer is that we need aging clocks when they do one of four things well.

First, they can be useful as research infrastructure — tools that make it easier to test hypotheses about mechanisms of aging over realistic timeframes. That is one reason the biomarker field remains central to geroscience.

Second, they can be useful as trial tools — not necessarily as approval-grade primary endpoints yet, but as enrichment markers, response monitors, and parallel measures that help determine whether an intervention touched aging-relevant biology.

Third, they can be useful as risk integrators, especially if they outperform chronological age and add something beyond conventional disease-specific models. This is where the recent proposal to think of biological age as risk-equivalent age is useful. A 2026 Nature Aging perspective argued that biological aging clocks should be reframed as a dynamic, risk-based metric that places an individual on a continuum of clinically meaningful risk, rather than as a metaphysical reading of some hidden true age.

Fourth, clocks can be useful as communication tools — a way of translating complex physiology into something a patient or trial participant can understand. But this is the weakest justification unless it is backed by the other three. A number that is intuitive but not actionable is still just a number.

The better question

So do we actually need aging clocks? Yes — but only if we stop asking them to be more universal than the biology allows. The field does not need endless new clocks that merely predict chronological age with cosmetic sophistication. It needs validated tools that are explicit about what they measure, what populations they work in, how uncertain their predictions are, and what decisions they are meant to inform.

In practice, that means the future probably belongs to clocks that are more specific, more interpretable, and more clinically anchored: pace-of-aging clocks rather than static age estimates, organ-specific clocks rather than generic averages, function-linked clocks rather than purely statistical age mimicry, and multimodal systems that compete honestly with direct outcome predictors instead of assuming their own superiority.

The field’s real goal was never to produce a more dramatic birthday. It was to build measures that make prevention, intervention, and translation possible. On that standard, aging clocks still matter. They just need to grow up.